ALB and Miyoshi myopathy: Nanoparticles encapsulating small-molecule chemotherapeutics, including albumin-based protein-drug conjugates formulated with paclitaxel (Abraxane; NCT01646762) and liposomal formulations of doxorubicin (Doxil and Myocet), are FDA-approved nanomedicine-based treatments for MM.